chemotherapy; the common side effects include acneiform (papulopustular) rash, diarrhea, edema, pruritus, dry skin, and alopecia. 5 Although there is a report of pneumatosis cystoides intestinalis (PCI) associated with the use of erlotinib in patients with lung cancer receiving erlotinib, 6 it has not yet been reported in patients with pancreatic cancer patients receiving erlotinib. The authors experienced a case of PCI in a 66-year old woman during chemotherapy with a combination of gemcitabine and erlotinib for treatment of advanced pancreatic cancer accompanied by hepatic metastasis; we report our experience with this case and review the related literature.
CASE
A 66-year-old woman was admitted to the hospital with a one month history of intermittent epigastric pain. She had no specific medical history except for taking oral medica- Abdominal computerized tomography (CT) scans revealed a 2.6 cm mass lesion around the pancreas neck (Fig. 1A, 1B) as well as multiple enlarged lymph nodes in peripancreatic areas including the para-aortic area. In addition, a metastatic lesion approximately 1 cm in size was observed in segment 4 of the liver (Fig. 1C) . Accordingly, she was clini- (Fig. 3) . Subsequent CT scans revealed intra-mural air along the ascending and the transverse colon, which was confirmed as valid findings for PCI (Fig. 4) . The patient was observed while fasting for 3 days, but no specific symptoms were observed. A follow-up abdominal X-ray examination showed reduced abnormal air deposition, and oral intake was resumed (Fig. 5) . We explained to the patient for possible complications and obtained consent for continued erlotinib-containing chemotherapy. Then, the patient was administered erlotinibcontaining chemotherapy and was discharged from the hospital. A follow-up X-ray showed complete resolution (Fig. 5) . Afterwards, the patient continued to receive chemotherapy with gemcitabine and erlotinib, and PCI was not observed through 16 th cycles of chemotherapy. However, at this time, the patient was found to have disease progression, and is currently undergoing treatment with oral fluoropyrimidine (TS-1).
DISCUSSION
PCI is a relatively rare disease characterized by gas formation in the submucosa or subserosa of the gastrointestinal tract. The pathogenesis of PCI remains unclear, but its potential causes include the loss of mucosal integrity, elevated intraluminal pressure, and intraluminal gas production such as bacterial overgrowth. Its clinical manifestations vary from incidental finding such as observed in the current case, to life-threatening conditions such as bowel necrosis or perforation. 7 The potential causes of PCI can be divided into gastrointestinal causes such as peptic ulcer, inflammatory bowel disease, and Clostridium infection, and non-gastrointestinal causes such as chronic obstructive pulmonary disease and endoscopic procedure. In rare cases, chemotherapy may also cause PCI. 8 Furthermore, molecular targeted therapies recently used for treatment of a various diseases may cause PCI. Among these therapies, bevacizumab is most commonly associated with PCI. 9 Development of PCI has been reported during treatment with erlotinib, such as this case, but previous case reports occurred in patients with lung cancer; thus, to our knowledge, this is the first case of PCI in a patient with pancreatic cancer.
The pathophysiology of gastrointestinal toxicity caused by EGFR tyrosine kinase inhibitors such as erlotinib is not yet known, but there is a convincing hypothesis that EGF may be involved in the maintenance of mucosal integrity. 10 In other words, EGF deficiency within intestinal mucosa due to erlotinib treatment may interfere with mucosal integrity, or portal venous gas; otherwise, conservative treatment alone should be sufficient. 8 In addition, inhalation oxygen therapy may be helpful, but there are limitations to its use in clinical practice without standardized optimal amounts and durations. 15 Because the patient in the current case had no symptoms such as abdominal pain at diagnosis and no abnormal blood test findings, she underwent conservative treatment only and thereafter improved.
Even with successful treatment, PCI recurs in about 30-40% within 18 months. 15 However, in the current case, there has been no further recurrence, despite continued use of the causative drug erlotinib.
The authors experienced a case of PCI during gemcitabine and erlotinib combination therapy in a patient with pancreatic cancer and liver metastasis. Although the patient was immunocompromised while receiving chemotherapy, her lack of symptoms suggested a conservative treatment plan.
Moreover, although she continued to use the causative drug 
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